305 related articles for article (PubMed ID: 33585182)
41. Management of metastatic bladder cancer.
Nadal R; Bellmunt J
Cancer Treat Rev; 2019 Jun; 76():10-21. PubMed ID: 31030123
[TBL] [Abstract][Full Text] [Related]
42. New and Emerging Therapies in the Management of Bladder Cancer.
Osterman CK; Milowsky MI
F1000Res; 2020; 9():. PubMed ID: 32983413
[TBL] [Abstract][Full Text] [Related]
43. Estimation of Percentage of Patients With Fibroblast Growth Factor Receptor Alterations Eligible for Off-label Use of Erdafitinib.
de Almeida Carvalho LM; de Oliveira Sapori Avelar S; Haslam A; Gill J; Prasad V
JAMA Netw Open; 2019 Nov; 2(11):e1916091. PubMed ID: 31755953
[TBL] [Abstract][Full Text] [Related]
44. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
45. Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions.
Lalani AA; McGregor BA; Albiges L; Choueiri TK; Motzer R; Powles T; Wood C; Bex A
Eur Urol; 2019 Jan; 75(1):100-110. PubMed ID: 30327274
[TBL] [Abstract][Full Text] [Related]
46. Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer.
Borcoman E; De La Rochere P; Richer W; Vacher S; Chemlali W; Krucker C; Sirab N; Radvanyi F; Allory Y; Pignot G; Barry de Longchamps N; Damotte D; Meseure D; Sedlik C; Bieche I; Piaggio E
Oncoimmunology; 2019; 8(5):e1581556. PubMed ID: 31069145
[TBL] [Abstract][Full Text] [Related]
47. Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges.
Pavan A; Attili I; Pasello G; Guarneri V; Conte PF; Bonanno L
J Immunother Cancer; 2019 Aug; 7(1):205. PubMed ID: 31383005
[TBL] [Abstract][Full Text] [Related]
48. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
Madden DL
Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148
[TBL] [Abstract][Full Text] [Related]
49. Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer.
Tong X; Tanino R; Sun R; Tsubata Y; Okimoto T; Takechi M; Isobe T
Respir Res; 2019 Dec; 20(1):270. PubMed ID: 31791326
[TBL] [Abstract][Full Text] [Related]
50. Current and future immunotherapy approaches in ovarian cancer.
Demircan NC; Boussios S; Tasci T; Öztürk MA
Ann Transl Med; 2020 Dec; 8(24):1714. PubMed ID: 33490226
[TBL] [Abstract][Full Text] [Related]
51. Targeting FGFR in bladder cancer: ready for clinical practice?
De Keukeleire S; De Maeseneer D; Jacobs C; Rottey S
Acta Clin Belg; 2020 Feb; 75(1):49-56. PubMed ID: 31671027
[No Abstract] [Full Text] [Related]
52. Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer.
Raoof S; Mulford IJ; Frisco-Cabanos H; Nangia V; Timonina D; Labrot E; Hafeez N; Bilton SJ; Drier Y; Ji F; Greenberg M; Williams A; Kattermann K; Damon L; Sovath S; Rakiec DP; Korn JM; Ruddy DA; Benes CH; Hammerman PS; Piotrowska Z; Sequist LV; Niederst MJ; Barretina J; Engelman JA; Hata AN
Oncogene; 2019 Sep; 38(37):6399-6413. PubMed ID: 31324888
[TBL] [Abstract][Full Text] [Related]
53. Erdafitinib Antagonizes ABCB1-Mediated Multidrug Resistance in Cancer Cells.
Feng W; Zhang M; Wu ZX; Wang JQ; Dong XD; Yang Y; Teng QX; Chen XY; Cui Q; Yang DH
Front Oncol; 2020; 10():955. PubMed ID: 32670878
[TBL] [Abstract][Full Text] [Related]
54. Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives.
Minguet J; Smith KH; Bramlage P
Int J Cancer; 2016 Jun; 138(11):2549-61. PubMed ID: 26537995
[TBL] [Abstract][Full Text] [Related]
55. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
[TBL] [Abstract][Full Text] [Related]
56. Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer.
Versteven M; Van den Bergh JMJ; Marcq E; Smits ELJ; Van Tendeloo VFI; Hobo W; Lion E
Front Immunol; 2018; 9():394. PubMed ID: 29599770
[TBL] [Abstract][Full Text] [Related]
57. Updates and novel treatments in urothelial carcinoma.
Hanna KS
J Oncol Pharm Pract; 2019 Apr; 25(3):648-656. PubMed ID: 30304985
[TBL] [Abstract][Full Text] [Related]
58. Clinical Relevance of Targeted Therapy and Immune-Checkpoint Inhibition in Lung Cancer.
Leone GM; Candido S; Lavoro A; Vivarelli S; Gattuso G; Calina D; Libra M; Falzone L
Pharmaceutics; 2023 Apr; 15(4):. PubMed ID: 37111737
[TBL] [Abstract][Full Text] [Related]
59. Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma.
Rizzo A; Ricci AD; Brandi G
Cancer Treat Res Commun; 2021; 27():100337. PubMed ID: 33611090
[TBL] [Abstract][Full Text] [Related]
60. Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date.
Moussa M; Papatsoris A; Abou Chakra M; Dellis A
Drug Des Devel Ther; 2021; 15():453-462. PubMed ID: 33603337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
